Out-of-balance bacteria is linked to multiple sclerosis − the ratio can predict severity of disease
Multiple sclerosis is a disease that results when the immune system mistakenly attacks the brain and spinal cord. It affects nearly one million people in the U.S. and over 2.8 million worldwide. While genetics play a role in the risk of developing multiple sclerosis, environmental factors such as diet, infectious disease and gut health are major contributors.
The environment plays a key role in determining who develops multiple sclerosis, and this is evident from twin studies. Among identical twins who share 100% of their genes, one twin has a roughly 25% chance of developing MS if the other twin has the disease. For fraternal twins who share 50% of their genes, this rate drops to around 2%.
Scientists have long suspected that gut bacteria may influence a person's risk of developing multiple sclerosis. But studies so far have had inconsistent findings.
To address these inconsistencies, my colleagues and I used what researchers call a bedside-to-bench-to-bedside approach: starting with samples from patients with multiple sclerosis, conducting lab experiments on these samples, then confirming our findings in patients.
In our newly published research, we found that the ratio of two bacteria in the gut can predict multiple sclerosis severity in patients, highlighting the importance of the microbiome and gut health in this disease.
First, we analyzed the chemical and bacterial gut composition of patients with multiple sclerosis, confirming that they had gut inflammation and different types of gut bacteria compared with people without multiple sclerosis.
Specifically, we showed that a group of bacteria called Blautia was more common in multiple sclerosis patients, while Prevotella, a bacterial species consistently linked to a healthy gut, was found in lower amounts.
In a separate experiment in mice, we observed that the balance between two gut bacteria, Bifidobacterium and Akkermansia, was critical in distinguishing mice with or without multiple sclerosis-like disease. Mice with multiple sclerosis-like symptoms had increased levels of Akkermansia and decreased levels of Bifidobacterium in their stool or gut lining.
To explore this further, we treated mice with antibiotics to remove all their gut bacteria. Then, we gave either Blautia, which was higher in multiple sclerosis patients; Prevotella, which was more common in healthy patients; or a control bacteria, Phocaeicola, which is found in patients with and without multiple sclerosis. We found that mice with Blautia developed more gut inflammation and worse multiple sclerosis-like symptoms.
Even before symptoms appeared, these mice had low levels of Bifidobacterium and high levels of Akkermansia. This suggested that an imbalance between these two bacteria might not just be a sign of disease, but could actually predict how severe it will be.
We then examined whether this same imbalance appeared in people. We measured the ratio of Bifidobacterium adolescentis and Akkermansia muciniphila in samples from multiple sclerosis patients in Iowa and participants in a study spanning the U.S., Latin America and Europe.
Our findings were consistent: Patients with multiple sclerosis had a lower ratio of Bifidobacterium to Akkermansia. This imbalance was not only linked to having multiple sclerosis but also with worse disability, making it a stronger predictor of disease severity than any single type of bacteria alone.
One of the most interesting findings from our study was that normally beneficial bacteria can turn harmful in multiple sclerosis. Akkermansia is usually considered a helpful bacterium, but it became problematic in patients with multiple sclerosis.
A previous study in mice showed a similar pattern: Mice with severe disease had a lower Bifidobacterium-to-Akkermansia ratio. In that study, mice fed a diet rich in phytoestrogens – chemicals structurally similar to human estrogen that need to be broken down by bacteria for beneficial health effects – developed milder disease than those on a diet without phytoestrogens. Previously we have shown that people with multiple sclerosis lack gut bacteria that can metabolize phytoestrogen.
Although the precise mechanisms behind the link between the Bifidobacterium-to- Akkermansia ratio and multiple sclerosis is unknown, researchers have a theory. Both types of bacteria consume mucin, a substance that protects the gut lining. However, Bifidobacterium both eats and produces mucin, while Akkermansia only consumes it. When Bifidobacterium levels drop, such as during inflammation, Akkermansia overconsumes mucin and weakens the gut lining. This process can trigger more inflammation and potentially contribute to the progression of multiple sclerosis.
Our finding that the Bifidobacterium-to-Akkermansia ratio may be a key marker for multiple sclerosis severity could help improve diagnosis and treatment. It also highlights how losing beneficial gut bacteria can allow other gut bacteria to become harmful, though it is unclear whether changing levels of certain microbes can affect multiple sclerosis.
While more research can help clarify the link between the gut microbiome and multiple sclerosis, these findings offer a promising new direction for understanding and treating this disease.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Ashutosh Mangalam, University of Iowa
Read more:
Newly discovered species of bacteria in the microbiome may be a culprit behind rheumatoid arthritis
Gut microbe imbalances could predict a child's risk for autism, ADHD and speech disorders years before symptoms appear
We looked at what supermarkets in 97 countries are doing to our waistlines. Here's what we found
Ashutosh Mangalam received funding from the NIH/NIAID, VA, and the University of Iowa. He holds a patent licensed to Evelo Biosciences by Mayo Clinic on a technology using Prevotella histicola to treat autoimmune diseases. No funds or products from this patent were used in this study.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
13 minutes ago
- Health Line
Primary Progressive MS: Myths vs. Facts
Misconceptions about primary progressive multiple sclerosis (PPMS) are common, especially since the condition can look different for everyone. Knowing what's true (and what's not) can help you feel more informed and empowered. Primary progressive multiple sclerosis (PPMS) is a complex condition that looks different from person to person. Symptoms, experiences, and rates of progression can vary widely. Because PPMS isn't as well-known as other types of multiple sclerosis (MS), myths and misconceptions often fill the gaps. That can make it harder to find trustworthy answers when you're trying to learn more about the condition. Here, we break down some of the most common myths about PPMS and share the facts behind them. Myth#1: There will never be a cure for PPMS Fact: While there's no cure yet, treatment options are expanding, and research is ongoing. In 2017, the Food and Drug Administration (FDA) approved Ocrevus (ocrelizumab) as the first disease-modifying therapy (DMT) for PPMS. In 2024, a new formulation called ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo), a subcutaneous injection administered twice a year, was approved. This new injection offers a quicker, approximately 10-minute administration alternative to the traditional intravenous infusion. Ocrevus and Ocrevus Zunovo are currently the only FDA-approved DMTs for PPMS. However, researchers are actively exploring new therapies. For instance, tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is undergoing phase 3 trials to assess its potential in slowing PPMS progression. Additionally, scientists are investigating treatments aimed at repairing myelin, the protective sheath around nerves damaged in MS. One such study involves combining metformin, a common diabetes medication, with clemastine, an antihistamine, to promote myelin repair. Myelin repair is important because it may help restore nerve function and slow disease progression. Although a cure for PPMS has yet to be found, these developments reflect a growing commitment to improving treatment options and outcomes. Myth: PPMS primarily occurs in females Fact: PPMS affects people of all sexes at the same rate. While relapsing-remitting multiple sclerosis (RRMS) is more common in people assigned female at birth (AFAB), affecting them two to three times more often than those assigned male at birth (AMAB), PPMS affects AFABs and AMABs in roughly equal numbers. It's important not to assume the type of MS based solely on sex. Regardless of gender, if you experience symptoms suggestive of MS, consult a healthcare professional for an accurate diagnosis. Myth: PPMS is an older person's disease Fact: PPMS typically begins in mid-adulthood, not old age. While PPMS tends to have a later onset than other forms of MS, it doesn't primarily affect older adults. On average, people with PPMS start experiencing symptoms around the age of 40. Myth: A PPMS diagnosis means you'll be disabled Fact: Disability progression in PPMS varies widely, and many people maintain mobility and independence for years. PPMS can lead to physical disability, but how quickly or whether it develops looks different for everyone. Some people notice gradual changes, while others may stay stable for long stretches of time. Not everyone will need mobility aids like canes or wheelchairs, especially early on. A 2022 study found that about 10% of people with MS experience severe disability within 5 years of diagnosis. That number rises to 25% within 10 years and then increases to 50% after 18 years. Still, this doesn't mean you should expect disability after receiving a PPMS diagnosis. The location of lesions, your overall health, and how early you begin treatment can all play a role in how the condition progresses. Working with your doctor on a treatment plan that includes physical or occupational therapy and regular movement can help you stay active and independent for longer. Myth: Having PPMS means you have to quit your job Fact: Many people with PPMS continue working, sometimes with a few adjustments. A PPMS diagnosis doesn't automatically mean you need to stop working. While symptoms like fatigue, changes in memory or thinking, or mobility issues can make certain jobs more challenging, many people with PPMS continue in full- or part-time work, especially in the early stages. Everyone's experience with PPMS is different, so your ability to work will depend on your specific symptoms and the demands of your job. If you're facing obstacles, workplace accommodations, like flexible hours, assistive devices, or ergonomic adjustments, may help you stay on the job. A conversation with your doctor or a vocational (work) counselor who understands chronic conditions can also help you explore options that support your health and independence. Myth: No medications help PPMS, so you should investigate natural remedies Fact: There are FDA-approved medications that can help slow the progression of PPMS, including ocrelizumab. While some natural remedies might offer symptom relief, they aren't always safe or proven to be effective. For years, there were no FDA-approved treatments for PPMS. That changed in 2017 when Ocrevus (ocrelizumab) became the first medication approved specifically for PPMS. In a study of 732 people with PPMS, those who received Ocrevus experienced a slower rate of disability progression compared to those who received a placebo. It remains the only approved disease-modifying therapy for this form of MS. Doctors may also prescribe medications to manage specific symptoms, such as antidepressants for mood changes or muscle relaxants for spasms. Some people turn to natural remedies like herbal supplements, acupuncture, or cannabis. Research into these options is ongoing, but so far, there's no strong evidence that they're safe or effective for treating MS symptoms. Some supplements can even interact with prescription drugs. If you're considering natural treatments, talk with your doctor first to avoid potential side effects or interactions. Myth: PPMS is ultimately an isolating disease — no one will understand what you're going through Fact: You're not alone, and you don't have to go through it alone either. While PPMS can feel isolating at times, many others are navigating similar challenges. It's estimated that nearly 1 million people in the United States are living with MS, and about 10% to 15% of them have PPMS. Thanks to growing awareness and advocacy, there are now more resources and support networks than ever. Support groups, both in-person and online, offer a space to connect with others who understand what you're going through. If group support isn't for you, that's OK too. Talking with a trusted friend, loved one, or therapist can still help ease feelings of isolation and improve emotional well-being. What matters most is finding a form of support that feels right for you. Myth: PPMS is deadly Fact: PPMS is a lifelong condition, but it's rarely fatal. The progressive nature of PPMS and the fact that there's no cure can understandably lead to fears about long-term outcomes. But while PPMS can affect mobility, thinking, and daily functioning, it's not considered a life threatening illness. Most people with MS who don't have severe disabilities can expect to live another 30 to 35 years after diagnosis. Recent research has shown that even after significant disease progression, many people continue to live for years. For example, after someone loses the ability to walk independently, on average, at around age 51, life expectancy is about 13 more years. Advances in treatment, early intervention, and lifestyle changes can help manage symptoms, reduce complications, and support overall health. Taking care of your physical and emotional well-being through exercise, a balanced diet, regular checkups, and support can make a big difference in quality of life. It's important to note that with ongoing advances in treatment, the outlook for people with PPMS continues to improve. Current data on disability and life expectancy may not reflect what's possible in the future. Takeaway Misconceptions about primary progressive multiple sclerosis (PPMS) can add confusion and fear to an already complex condition. However, the reality is that PPMS doesn't always follow the path people expect. From treatment options to life expectancy, the facts paint a more hopeful and nuanced picture. While every experience with PPMS is different, understanding the reality behind the myths can help you make informed choices, find support, and feel more in control of your journey.
Yahoo
5 hours ago
- Yahoo
'Gambling addiction cost my sick mum thousands'
The daughter of a woman who became addicted to slot machines and lost thousands while undergoing cancer treatment is calling on the government to introduce tougher controls. Jackie Olden said her late mother Wendy Hughes got hooked after working at a bookmakers where she was asked to play the machines on a free demonstration mode to help drum up customer interest. She said it prompted Ms Hughes, who died from cancer in 2024 at the age of 64, to begin playing slots in her own time before spiralling into debt. Ms Olden said: "My mum was never someone who would have gambled before this, she was absolutely dedicated to her family." She said her mother, a widow, had worked hard to make ends meet while raising her three children in Stockport, Greater Manchester. "She had her own house and some money saved but all of that just went and it went really, really, really quickly," Ms Olden said. Ms Hughes's children intervened in an attempt to get her excluded from gambling outlets but she relapsed years later after discovering 24-hour adult gaming centres. Ms Olden said: "When I found out, I was absolutely flabbergasted to hear that there are 24-hour slot machine places on almost every high street in the UK. "In Stockport, where I live, there are three of them." Ms Hughes continued gambling after being diagnosed with cancer in April 2023 and became progressively more unwell. In November of the same year, she lost almost £2,000 pounds in two sessions at the Merkur slots venue in Stockport. The German company was fined £95,450 earlier this year by the Gambling Commission following a complaint by Ms Hughes, which found the operator failed "to follow rules aimed at keeping consumers safe from harm". In a bid to protect others, Ms Olden earlier delivered a petition with more than 40,000 signatures to Downing Street, calling on the government to give local government stronger powers to refuse licences for gambling venues where concerns are raised. She said: "I'm not an anti-gambling purist or someone who wants to tell people what to do, but these places are so dangerous. "The products in there are known to be the most harmful, the most addictive and I just think we need to regulate them way more tightly." Merkur said the the failure was "due to premises staff not implementing our policies and procedures effectively". They continued: "Customer welfare is our priority and we have conducted a thorough internal review. "As a result, we have strengthened training for our 1,840 venue-based staff as well as enhancing reporting procedures to ensure our high standards are upheld." Listen to the best of BBC Radio Manchester on Sounds and follow BBC Manchester on Facebook, X, and Instagram. You can also send story ideas via Whatsapp to 0808 100 2230. Slot machines to go cashless as debit cards allowed
Elle
10 hours ago
- Elle
Science Unpacks the Healing Potential of Your Own Blood
Every item on this page was chosen by an ELLE editor. We may earn commission on some of the items you choose to buy. If you were to shrink yourself down to smaller than a sugar crystal and travel into someone's veins like Ms. Frizzle and her Magic School Bus, you'd see that blood isn't the free-flowing river depicted in your childhood storybooks. Rather, you'd find an intricate ecosystem suspended in plasma: disc-like red blood cells carrying oxygen through the body; bumpy white blood cells warding off infection; and tiny platelets with octopus-like tentacles directing healing. Rich in growth factors, platelets are often considered the gold standard for regenerative medicine. In platelet-rich plasma treatments, or PRP, doctors spin a patient's blood in a centrifuge to single out the platelets and the plasma, creating a healing elixir that can be added back into a patient's body. PRP has long been used for promoting hair growth, improving skin, and healing injuries. The next generation of PRP is called PRF, which may offer more sustained healing and collagen production over time. 'PRF stands for 'platelet-rich fibrin,'' says Lara Devgan, MD, a plastic surgeon in New York. 'It harnesses the body's own growth factors to stimulate collagen, improve skin texture, and restore volume without fillers.' For patients, PRP and PRF extractions for cosmetic or therapeutic use just involve a simple blood draw. They're much less expensive than a hair transplant, and may produce a more natural result than other skin injectables. If PRP is an iPhone, PRF is the Pro version, leading to potentially longer-lasting results. This may be because it contains fibrin, which aids in blood clotting; a 2011 study in Annals of Maxillofacial Surgery found that PRF may speed healing, since it helps the body form new blood vessels. Thanks to fibrin, PRF unleashes growth factors more slowly than PRP. Because it's mixed at a higher speed, PRP expels a flood of growth factors—which act like messengers between and within cells, pinging information back and forth to ensure everything is in tip-top shape—all at once. In contrast, PRF releases these healing agents over 7 to 10 days, which may enhance tissue regeneration, says Gabriel Chiu, DO, a plastic surgeon in Beverly Hills. PRF was developed to bypass some of PRP's limits. PRP is often mixed with anticoagulants, which in some cases may cause allergic reactions and hinder the platelets' regenerative power, according to a 2020 study published in Frontiers in Bioengineering and Biotechnology. PRF, which is spun more slowly, is made without anticoagulants and so 'has the least risk for someone [with] sensitivity issues,' Chiu explains. Still, both Devgan and Chiu agree that in some cases, PRP remains the better option. It's an easier-to-disperse fluid, so it's better for larger treatment areas. PRP is best for hair loss, since it can be micro-needled in, whereas PRF's thicker solution must be injected. But when it comes to targeted treatment for lines, wrinkles, and hollow under-eyes, PRF may be the more potent remedy since it softens the face, according to Chiu. He also uses PRF as a 'glue' when he does a facelift. It helps tissues adhere to each other, and may boost healing. Though PRF can appear to 'fill' under-eye hollows by helping skin quality and firmness, it won't add volume, like filler. A PRF treatment is akin to upping the thread count of your sheets, Devgan says. Skin enhanced by PRF versus normal skin is like the difference between sheets made from 350-thread-count Egyptian cotton and run-of-the mill 200-thread-count sheets. 'It's not like making a bedsheet into a comforter,' she says. But who doesn't want an amazing set of sheets? A version of this story appears in the Summer 2025 issue of ELLE. GET THE LATEST ISSUE OF ELLE
